The goal of Advanced Oncotherapy (LON:AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In ...
Read Article »Advanced Oncotherapy Analyst Q&A with Dr Martin Hall (LON:AVO)
Advanced Oncotherapy (LON:AVO) is the topic of conversation when Hardman and Co’s Head of Life Sciences Dr Martin Hall caught up with DirectorsTalk for an exclusive interview. Q1: You recently ...
Read Article »Why is Advanced Oncotherapy well positioned for the future?
Advanced Oncotherapy plc (LON: AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting ...
Read Article »Advanced Oncotherapy Commercialising a breakthrough technology
Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement ...
Read Article »Advanced Oncotherapy Preparing for commercialisation
Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by ...
Read Article »Advanced Oncotherapy Important regulatory milestone: ISO approval
Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has ...
Read Article »Advanced Oncotherapy Four components integrated
Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones ...
Read Article »Advanced Oncotherapy LIGHT system remains on-track with reduced overall technology risk profile
Advanced Oncotherapy Plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today its audited results for the year ended 31 December 2017, another year of ...
Read Article »Advanced Oncotherapy Strengthens balance sheet position
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that the Company has received £10 million from Yantai Cipu, through its affiliated entity ...
Read Article »Advanced Oncotherapy Plc Successful testing supporting the superior clinical outcomes of LIGHT
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, provided today the following technological update. The LIGHT system has been designed to electronically control the ...
Read Article »